Neuphoria Therapeutics Inc. Common Stock
Symbol: NEUP (NASDAQ)
5.18
▼ (-66.40%) -10.225
Company Description:
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators.
Key Stats
- Today's Open: $4.9
- Today's High: $5.72
- Today's Low: $4.652
- Today's Volume: 1.94M
- Yesterday Close: $15.4
- Yesterday High: $17.19
- Yesterday Low: $15.21
- Yesterday Volume: 813.82K
- Last Min Volume: 516
- Last Min High: $5.175
- Last Min Low: $5.17
- Last Min VWAP: $5.17265
Company Profile
- Name: Neuphoria Therapeutics Inc. Common Stock
- Website: https://www.neuphoriatx.com
- Listed Date: 2021-12-16
- Location: BURLINGTON, MA
- Market Status: Active
- CIK Number: 0001191070
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $36.31M
- Round Lot: 100
- Outstanding Shares: 2.36M
- Asset Type: ADRC
RECENT FILINGS FOR NEUP
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-20 | 424B5 | View |
| 2025-10-20 | 8-K | View |
| 2025-09-29 | 10-K | View |
| 2025-09-23 | 424B5 | View |
| 2025-09-16 | 8-K | View |
| 2025-09-02 | 4 | View |
| 2025-07-29 | 424B5 | View |
| 2025-07-18 | 8-K | View |
| 2025-05-20 | 8-K | View |
| 2025-05-20 | 10-Q | View |
| 2025-05-19 | 4/A | View |
| 2025-05-15 | NT 10-Q | View |
| 2025-04-18 | 4 | View |
| 2025-04-18 | 4 | View |
| 2025-04-18 | 4 | View |
| 2025-04-18 | 4 | View |
| 2025-04-18 | 4 | View |
| 2025-02-14 | SCHEDULE 13G/A | View |
| 2025-02-14 | 10-Q | View |
| 2025-02-12 | 424B5 | View |